REVENUE (Tables)

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table summarizes our CCA revenue (in thousands):

	Three Months Ended March 31,
	2020		2019
Point of Care laboratory revenue:	$	17,096	$	15,961
Consumables	14,248		12,317
Sales-type leases	1,244		1,742
Outright instrument sales	1,205		1,528
Other	399		374
Point of Care imaging revenue:	4,855		5,410
Outright instrument sales	4,055		4,546
Other	800		864
Other CCA revenue:	5,355		3,345
Other pharmaceuticals, vaccines and diagnostic tests	5,329		3,246
Research and development, license and royalty revenue	26		99
Total CCA revenue	$	27,306	$	24,716

The following table summarizes our OVP revenue (in thousands):

	Three Months Ended March 31,
	2020		2019
Contract manufacturing	$	3,191	$	4,666
License, research and development	157		129
Total OVP revenue	$	3,348	$	4,795

Schedule of Timing of Revenue Expected to be Recognized

As of March 31, 2020, the Company expects to recognize revenue as follows (in thousands):

Year Ending December 31,	Revenue
2020 (remaining)	$	21,055
2021	25,661
2022	22,458
2023	19,697
2024	15,470
Thereafter	17,747
	$	122,088